Drug Profile
Terbinafine topical - Moberg Pharma AB
Alternative Names: MOB-015; MOB015B; Terbinafine 10%; Terclara®Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Moberg Derma
- Developer Allderma; Moberg Pharma
- Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
- Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Onychomycosis
Most Recent Events
- 07 Feb 2024 Launched for Onychomycosis in Sweden (Topical)
- 06 Oct 2023 Moberg Pharma completes enrolment in a phase III trial in Onchomycosis (In adolescents, In adults, In elderly) in USA and Canada (Topical) (NCT05279846)
- 05 Jul 2023 Registered for Onychomycosis in Norway, Iceland, Liechtenstein, European Union (Topical)